Protection of moderna and pfizer vaccines is evaluated from SARS-COV-2 options

Researchers from the United States have shown that MRNA-vaccines have been protected from most new variants of coronavirus infection, including the “Delta” -Stamma. An article by scientists with evaluation of the effectiveness of vaccines was accepted for publication in the journal Nature.

Specialists from Yale University from November 2020 to January 2021 collected from 40 medical professionals blood samples before the latter received the first dose of Moderna or Pfizer. After that, for 98 days, the researchers did five blood fences at volunteers – seven and 28 days after the first dose and seven, 28 and 70 days after the second.

blood samples were exposed to 16 different options for SARS-COV-2 and measured the production of antibodies and T cells in response to the virus. The researchers discovered an increased immune response in all blood samples – although the response force ranged from a person to a person. The immune response to the “Delta” -variant was generally strong and intensified after receiving volunteers of second doses of vaccines. According to the researchers, the cases of infection of Delta-Range vaccinated people are explained by its extremely high contamination, and not the disadvantages in the work of vaccines. However, to the surprise of scientists, the immune response caused by vaccines most, but options combining two mutations in the receptor-binding domain of the virus (E484K and N501Y / T) – “beta” and “gamma” -varisa.

Also, the immune response was stronger from those who were silent to COVID-19 before vaccination. “Recovery after the initial infection is similar to the first dose of the vaccine,” says one of the researchers, Professor of immunobiology Akiko Ivasaki. According to the researchers, this indicates that revaccination can be an effective measure for containing coronavirus infection.

/Media reports.